Your browser is no longer supported. Please, upgrade your browser.
Settings
BCEL Atreca, Inc. daily Stock Chart
BCEL [NASD]
Atreca, Inc.
Index- P/E- EPS (ttm)-2.68 Insider Own2.40% Shs Outstand28.02M Perf Week-7.64%
Market Cap412.63M Forward P/E- EPS next Y-2.96 Insider Trans-21.42% Shs Float14.72M Perf Month6.06%
Income-74.30M PEG- EPS next Q-0.76 Inst Own85.50% Short Float12.10% Perf Quarter-32.62%
Sales- P/S- EPS this Y-70.30% Inst Trans3.73% Short Ratio8.33 Perf Half Y82.34%
Book/sh6.07 P/B3.03 EPS next Y0.60% ROA-36.50% Target Price28.63 Perf Year-
Cash/sh6.73 P/C2.73 EPS next 5Y- ROE-38.10% 52W Range9.51 - 29.35 Perf YTD18.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.38% Beta-
Dividend %- Quick Ratio22.50 Sales past 5Y- Gross Margin- 52W Low90.17% ATR1.62
Employees118 Current Ratio22.50 Sales Q/Q- Oper. Margin- RSI (14)53.13 Volatility7.44% 9.18%
OptionableNo Debt/Eq0.00 EPS Q/Q-43.70% Profit Margin- Rel Volume0.61 Prev Close18.38
ShortableYes LT Debt/Eq0.00 EarningsMar 03 Payout- Avg Volume214.00K Price18.09
Recom1.60 SMA20-0.54% SMA508.11% SMA20016.24% Volume85,690 Change-1.60%
Apr-22-20Initiated Wedbush Outperform $27
Apr-22-20Initiated H.C. Wainwright Buy $30
Apr-16-20Initiated Robert W. Baird Outperform $30
Sep-04-19Initiated ROTH Capital Buy $30
Jul-15-19Initiated Stifel Buy $28
Jul-15-19Initiated Evercore ISI Outperform
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated Canaccord Genuity Buy $23
May-21-20 08:00AM  
May-14-20 04:30PM  
May-13-20 05:00PM  
May-12-20 04:30PM  
Apr-06-20 04:30PM  
Mar-12-20 05:33PM  
Mar-11-20 04:30PM  
Feb-24-20 04:30PM  
Feb-13-20 04:30PM  
Feb-05-20 04:05PM  
Dec-26-19 10:48AM  
Dec-19-19 04:54PM  
Dec-03-19 08:00AM  
Nov-14-19 08:00AM  
Nov-12-19 04:05PM  
Nov-05-19 08:00AM  
Sep-19-19 09:19AM  
Aug-26-19 04:05PM  
Aug-17-19 07:30AM  
Aug-13-19 04:05PM  
Jul-15-19 02:22PM  
Jul-11-19 08:00AM  
Jun-20-19 11:16AM  
Jun-19-19 09:40PM  
08:20AM  
Jun-17-19 10:07AM  
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greenberg Norman MichaelChief Scientific OfficerJun 01Option Exercise4.5615,00068,40015,000Jun 03 05:03 PM
Greenberg Norman MichaelChief Scientific OfficerJun 01Sale18.3815,000275,7600Jun 03 05:03 PM
Robinson William HewittDirectorMay 28Sale20.0160012,003429,861May 29 06:50 PM
Serafini TitoChief Strategy OfficerMay 27Sale20.001002,000456,620May 29 06:48 PM
Robinson William HewittDirectorMay 26Sale20.003877,740430,461May 27 05:58 PM
Serafini TitoChief Strategy OfficerMay 26Sale20.002004,000456,720May 27 05:57 PM
Serafini TitoChief Strategy OfficerMay 18Sale20.001,70034,004456,920May 19 05:39 PM
Robinson William HewittDirectorMay 18Sale20.001,60032,003430,848May 19 05:41 PM
Robinson William HewittDirectorMay 15Sale20.002,10042,000432,448May 19 05:41 PM
Serafini TitoChief Strategy OfficerMay 15Sale20.002,20044,000458,620May 19 05:39 PM
Robinson William HewittDirectorMay 13Sale16.825,00084,105434,548May 15 05:45 PM
Serafini TitoChief Strategy OfficerMay 11Sale18.0010,000180,025460,820May 13 07:35 PM
Greenberg Norman MichaelChief Scientific OfficerMay 07Option Exercise4.565,00022,8005,000May 08 05:28 PM
Greenberg Norman MichaelChief Scientific OfficerMay 07Sale18.005,00090,0000May 08 05:28 PM
Greenberg Norman MichaelChief Scientific OfficerMay 01Option Exercise4.5610,00045,60010,000May 04 05:57 PM
Greenberg Norman MichaelChief Scientific OfficerMay 01Sale15.0310,000150,2760May 04 05:57 PM
Serafini TitoChief Strategy OfficerApr 16Sale16.2810,000162,761470,820Apr 20 05:32 PM
Robinson William HewittDirectorApr 16Sale16.255,00081,271439,548Apr 20 05:30 PM
Greenberg Norman MichaelChief Scientific OfficerApr 14Option Exercise4.565,00022,8005,000Apr 16 06:28 PM
Greenberg Norman MichaelChief Scientific OfficerApr 14Sale18.005,00090,0000Apr 16 06:28 PM
Greenberg Norman MichaelChief Scientific OfficerApr 08Option Exercise4.568,00036,4808,000Apr 10 05:17 PM
Greenberg Norman MichaelChief Scientific OfficerApr 08Sale15.018,000120,1010Apr 10 05:17 PM
Greenberg Norman MichaelChief Scientific OfficerApr 01Option Exercise4.562,0009,1202,000Apr 02 06:18 PM
Greenberg Norman MichaelChief Scientific OfficerApr 01Sale15.212,00030,4220Apr 02 06:18 PM
Orwin John APresident & CEOMar 17Buy12.796,00076,7406,000Mar 19 06:52 PM
Greenberg Norman MichaelChief Scientific OfficerMar 02Option Exercise4.5615,00068,40015,000Mar 04 06:18 PM
Greenberg Norman MichaelChief Scientific OfficerMar 02Sale24.0715,000360,9840Mar 04 06:18 PM
Cavet GuyChief Technical OfficerFeb 25Option Exercise4.562,1009,57694,858Feb 26 06:24 PM
Cavet GuyChief Technical OfficerFeb 25Sale20.647,100146,53887,758Feb 26 06:24 PM
Greenberg Norman MichaelChief Scientific OfficerFeb 03Option Exercise4.5615,00068,40015,000Feb 04 06:00 PM
Greenberg Norman MichaelChief Scientific OfficerFeb 03Sale19.6515,000294,7680Feb 04 06:00 PM
Cavet GuyChief Technical OfficerJan 27Sale20.0010,000200,00092,758Jan 29 04:05 PM
Greenberg Norman MichaelChief Scientific OfficerJan 24Option Exercise4.565,00022,8005,000Jan 27 04:10 PM
Greenberg Norman MichaelChief Scientific OfficerJan 24Sale18.475,00092,3460Jan 27 04:10 PM
Greenberg Norman MichaelChief Scientific OfficerJan 17Option Exercise4.5610,00045,60010,000Jan 22 04:15 PM
Cavet GuyChief Technical OfficerJan 17Option Exercise5.161,9199,902109,677Jan 22 04:16 PM
Cavet GuyChief Technical OfficerJan 17Sale14.906,919103,065102,758Jan 22 04:16 PM
Greenberg Norman MichaelChief Scientific OfficerJan 17Sale14.9010,000148,9920Jan 22 04:15 PM